Introduction
Although the favourable effects of statins on the prevention of coronary heart disease complications are now well documented in secondary and primary prevention, much is still obscure in their preventive mechanism of action. It is of note that, eg, in both 4S and CARE only part of coronary end points could be prevented in the active treatment group. 1 If the first possibility is true, it is important to find new approaches to statin treatment. As atorvastatin also reduces efficiently triglycerides, 3 it could be thought to affect favourably on the so-called atherogenic lipid profile (ALP, 1)-characterised by small dense LDL particles, insulin resistance LDL particles susceptible to oxidation (low vitamin E content). ALP has been implicated as a very important part of coronary risk and triglycerides may play an important part in this profile: correlation between LDL diameter and serum triglycerides has been reported to be −0.71. 4 Statin studies with clinical end points have thus far involved only approximately 10% decrease in serum triglycerides. Older statins do not seem to affect LDL composition substantially. 5 Preliminary studies have indicated that in 4S, simvastatin prevented coronary events more efficiently in those with high cholesterol synthesis and low cholesterol absorption. 6 On the other hand, we have recently shown that high cholesterol synthesis (simply reflected by high serum precursor sterol levels) and concomitantly low absorption of cholesterol (simply reflected by low serum plant sterol levels) are associated with characteristics of the metabolic syndrome X. 7 Fibrates are often thought as drug of choice in these patients as in the Helsinki Heart Study the great majority of the clinical benefit was confined to a subset of individuals with elevated triglycerides and low HDL cholesterol. 8 For example, in 4S patients with triglycerides over 2.5 mmol/l were excluded. Thus, atorvastatin may have a powerful and more efficient effect on coronary event reduction, and therefore it is important that the effects of atorvastatin on ALP and metabolic syndrome are accurately documented in a representative cohort of subjects at risk.
If the second possibility is true, then it would be very important to recognise those patients who do not respond to statins at all and find alternative therapies for them. The importance of focusing trial results better to individuals has been recently stressed. 9 Overall, statin treatment in primary prevention can only gain wide acceptance if it can be targeted properly. This is because-despite even highly statistically significant clinical benefit-costeffectiveness is probably not acceptable, if number needed to be treated is high. 10 Characterisation of non-responders will include simple baseline ratios of total cholesterol to HDL cholesterol, serum apolipoproteins and other variables in ALP, antioxidant/oxidant capacity of LDL particle, serum non-cholesterol sterols and homocysteine, and simple indicators of glucose metabolism.
Several lines of evidence now indicate that oxidation of LPL is a key step in atherogenesis. Oxidation alters biological properties of LDL, and these alterations lead to the development of atherosclerosis and endothelial dysfunction. 11, 12 The data on LDL oxidation comes almost exclusively from experimental in vitro studies, where isolated LDL fractions have been exposed to oxidative stress, induced by a wide range of chemical or physiological stimuli. 12 In one such study, HMG-CoA reductase inhibitor was found to inhibit oxidation of LDL by human macrophages. 13 Ahotupa et al 14, 15 have recently developed new methods for the direct measurement of oxidation products (LDL baseline diene conjugation, LDL-BDC) and antioxidant potential of circulating LDL in vivo. 15 These methods are fast and simple to perform and can, therefore, be applied to clinical purposes. The validity and clinical applicability of these methods have been demonstrated by several studies (see below). [17] [18] [19] [20] [21] By this method, we recently observed that subjects having two or three vessels coronary artery disease who used lipid-lowering drugs had 18% lower LDL-BCD than subjects with similar disease but without lipid-lowering drugs (unpublished study).
Objective of the sub-study
The aim of the study is to elucidate baseline lipid (including the level of LDL oxidation) and other characteristics which best predict individual clinical response to atorvastatin treatment. Our hypothesis is that atorvastatin treatment will be especially efficient to prevent coronary end points in patients who have atherogenic lipoprotein profile, high hepatic cholesterol synthesis and subclinical signs of impaired glucose homeostasis.
We have the approval of the Ethical Committee of Helsinki University Hospital dated on the 15th April 1998.
Methods
The following variables characterising ALP will be measured in the Finnish ASCOT patients:
• measurement of waist:hip ratio, • total cholesterol: HDL-cholesterol ratio, • serum cholesterol precursor sterol lathosterol (reflects hepatic cholesterol synthesis), GLC using a 50-m long capillary column, • serum cholesterol and serum plant sterols (reflect cholesterol absorption) GLC using a 50-m long capillary column, • serum homocysteine (subsample of 300), • plasma fibrinogen, • LDL oxidation and antioxidant potential (subsample of 400).
For the measurements venous blood samples will be collected from seated subjects at 7.30-8.00 am after 12 h of fasting. Serum will be separated by centrifugation and thereafter stored at −70°C until analysed.
Discussion
This sub-study was aimed to be carried out in two out of three (the two southern regions) Finnish ASCOT regions. Thus, the centres in and around the three largest cities in Finland (Helsinki, Tampere and Turku) are going to participate in this study. The original idea was to have baseline data from all and a random subsample after 6 and 12 months treatment in patients recruited in the lipid arm. However, because this sub-study was not a mandatory part of the main study, we have so far blood samples from 160 patients only. Thus, we do not have enough power to relate the baseline variables or possible changes caused by the treatment to the end points. We can only compare changes in the variables measured in four different treatment categories that are amlodipine with and without atorvastatin and atenolol with and without atorvastatin. The results are reported later.
